TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
about
Immunotherapy for cancer in the central nervous system: Current and future directionsCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyThe Role of Toll-Like Receptors in Hematopoietic MalignanciesTwo in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer.Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells.Drugging Membrane Protein Interactions.The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition.Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Towards the next generation of biomedicines by site-selective conjugation.Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancerEnhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.Toll-Like Receptor Activation in Immunity vs. Tolerance.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Cancer immunotherapy beyond immune checkpoint inhibitors.Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1β production.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
P2860
Q26750765-C41FD52C-C082-4E89-9D8F-0D114EE9BC3CQ28066199-84D868CF-012D-45A8-B684-2AE3EBAB5478Q28077740-0F7EBCD3-7B33-4D93-9AFF-4A4666545464Q34931968-690E6694-1351-4501-A466-E98BEB69C36BQ36082731-8ED012A9-7A21-40F8-A60C-05F0B28B6DD0Q36821236-5B02FA5E-037C-4C77-B148-5DCC13FDC94DQ37143137-B4C8F9A2-B743-43F1-B782-9B54DEB9702BQ38264904-C126D305-5E0A-4FB4-BD7B-1EC08EBC484FQ38453610-283C52B8-935D-45F3-84B1-097D88673B94Q38706553-C56D2A1F-69C6-4A18-B25D-F860F69C00DCQ38706944-D16B30AF-1BA5-4BAB-8E4D-ECDC632F210CQ38912287-B3C47AFB-5599-4B47-9A08-586F59BA19A3Q38971847-8F21701A-DAB4-443E-B668-43A887BF0659Q41324342-8A630658-1347-4F36-9CC6-7D0D3199258BQ46047154-0D310D06-30E6-4D09-BA1A-D90D9EDBEB25Q47554248-5B4C17E3-CBFF-4914-9A8D-F91F8C55F0CEQ48507691-B895042C-5356-4DF9-8A26-17EA020C0DE1Q52653710-B2B5AE64-8611-49D0-AFA8-D0359A7363E2Q55156621-1DD7FF8B-495F-49C2-BCBD-F7BDDB136B51
P2860
TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
TLR Agonists for Cancer Immuno ...... ulatory and Inhibitory Effects
@en
type
label
TLR Agonists for Cancer Immuno ...... ulatory and Inhibitory Effects
@en
prefLabel
TLR Agonists for Cancer Immuno ...... ulatory and Inhibitory Effects
@en
P2860
P356
P1476
TLR Agonists for Cancer Immuno ...... ulatory and Inhibitory Effects
@en
P2093
Hailing Lu
P2860
P356
10.3389/FIMMU.2014.00083
P577
2014-03-03T00:00:00Z